Related Experiment Video
Updated: Jun 13, 2025
A Strategy to Identify de Novo Mutations in Common Disorders such as Autism and Schizophrenia
Published on: June 15, 2011
A pilot study: Examining cytoskeleton gene expression profiles in Pakistani children with autism spectrum disorder
Sana Malik1, Syed Aoun Ali2, Ahmed Murtaza Mehdi3
1Kauser Abdullah Malik School of Life Sciences, Forman Christian College (A Chartered University) Lahore, Lahore, Pakistan.
Insights
This study explored cytoskeleton-linked genes (profilins and ERM proteins) in Pakistani children with autism spectrum disorder (ASD). Gene expression patterns successfully predicted potential drug-gene interactions for future ASD treatments.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Autism spectrum disorder (ASD) presents complex challenges in cognitive, emotional, and social development.
- Effective pharmacological interventions for neurodevelopmental disorders are urgently needed.
- This study focuses on diagnosing and identifying treatments for ASD in Pakistani children.
Purpose of the Study:
- To explore non-invasive diagnostic methods for ASD in Pakistani children.
- To quantify expression patterns of profilins (PFN1, 2, 3) and ERM proteins (ezrin, radixin, moesin) in saliva samples.
- To identify potential drug-gene interactions for ASD treatment.
Main Methods:
- Qualitative polymerase chain reaction (PCR) to analyze gene expression of profilin and ERM genes in saliva samples from children with ASD (n=22).
- Sparse partial least squares discriminant analysis (sPLS-DA) model to predict drug-gene responses.
- Development of connectivity maps to visualize predicted drug-gene associations for 24 drugs.
Main Results:
- Varied expression profiles of cytoskeleton-linked genes (profilins and ERM) were observed in children with ASD.
- The sPLS-DA model accurately predicted drug-gene responses.
- Sixteen drugs showed significant positive correlations, while eight showed negative correlations with targeted gene expression.
Conclusions:
- Cytoskeleton-linked genes (PFN and ERM) play a role in ASD.
- Quantitative gene expression successfully predicted drug-gene interactions.
- These findings support the potential clinical use of identified drugs for treating individuals with ASD in future research.
Background:
Finding effective pharmacological interventions to address the complex array of neurodevelopmental disorders is currently an urgent imperative within the scientific community as these conditions present significant challenges for patients and their families, often impacting cognitive, emotional, and social development. In this study, we aimed to explore non-invasive method to diagnose autism spectrum disorders (ASD) within Pakistan children population and to identify clinical drugs for its treatment.
Aims:
The current report outlines a comprehensive bidirectional investigation showcasing the successful utilization of saliva samples to quantify the expression patterns of profilins (PFN1, 2, and 3); and ERM (ezrin, radixin, and moesin) proteins; and additionally moesin pseudogene 1 and moesin pseudogene 1 antisense (MSNP1AS). Subsequently, these expression profiles were employed to forecast interactions between drugs and genes in children diagnosed with ASD.
Methods:
This study sought to delve into the intricate gene expression profiles using qualitative polymerase chain reaction of profilin isoforms (PFN1, 2, and 3) and ERM genes extracted from saliva samples obtained from children diagnosed with ASD. Through this analysis, we aimed to elucidate potential molecular mechanisms underlying ASD pathogenesis, shedding light on novel biomarkers and therapeutic targets for this complex neurological condition. (n = 22). Subsequently, we implemented a diagnostic model utilizing sparse partial least squares discriminant analysis (sPLS-DA) to predict drugs against our genes of interest. Furthermore, connectivity maps were developed to illustrate the predicted associations of 24 drugs with the genes expression.
Results:
Our study results showed varied expression profile of cytoskeleton linked genes. Similarly, sPLS-DA model precisely predicted drug to genes response. Sixteen of the examined drugs had significant positive correlations with the expression of the targeted genes whereas eight of the predicted drugs had shown negative correlations.
Conclusion:
Here we report the role of cytoskeleton linked genes (PFN and ERM) in co-relation to ASD. Furthermore, variable yet significant quantitative expression of these genes successfully predicted drug-gene interactions as shown with the help of connectivity maps that can be used to support the clinical use of these drugs to treat individuals with ASD in future studies.
